Clinical trials: Diabetes Mellitus Progression
Type 1 Diabetes
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).
- Trial name
- SAFEGUARD (NCT07187531)
- Testing
- High Dose SAB-142, Low Dose SAB-142
- Where
- 68 sites in United States, Australia and 13 more
- Volunteers
- 159 people
- Sponsor
- SAb Biotherapeutics, Inc.
Type 1 Diabetes
Effects Of Gamma Aminobutyric Acid On The Progression Of New Onset Juvenile Type 1 Diabetes
This study is a multicenter, randomized, double-masked, placebo-controlled clinical study. All groups will receive standard intensive diabetes treatment with insulin and life style management.
- Trial name
- NCT01781884
- Testing
- Gamma Aminobutyric Acid (GABA)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Huashan Hospital
Type2 Diabetes
[11C]5-Hydroxy-tryptophan PET for Assessment of Islet Mass in Type 2 Diabetes
Cross-sectional study to investigate subjects at different stages of type 2 diabetes development with expected stratification of pancreatic islet mass. Non-diabetic individuals were assigned as control.
- Trial name
- NCT02967354
- Testing
- Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Per-Ola Carlsson
Diabetes Mellitus, Type 1
Polyclonal Anti-T-Lymphocyte Globulin (ATG) in Type 1 Diabetes
The primary objective of the study is: To compare the effect of ATG treatment together with intensified insulin therapy (Group 1) on fasting and glucagon-stimulated C-peptide production with that of intensified insulin therapy…
- Trial name
- NCT00190502
- Testing
- Polyclonal anti-T-cell antibodies
- Where
- Czechia
- Volunteers
- 28 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Type 1 Diabetes
Immune Function and the Progression to T1D
To elucidate the mechanisms by which type 1 diabetes-associated genes; IFIH1, TYK2, IKZF4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune…
- Trial name
- NCT05899439
- Testing
- blood draw
- Where
- 3 sites in United States
- Volunteers
- 2,800 people, healthy volunteers welcome
- Sponsor
- University of Florida
Diabetes Mellitus
Effect of GABA Supplementation in the Progression of Type 1 Diabetes in Children
Type 1 diabetes mellitus (T1DM) is an autoimmune disease in which the body's immune system attacks and destroys the insulin producing beta cells of the pancreas.
- Trial name
- GABA (NCT01561508)
- Testing
- gamma-amino-butyric acid, Xylitol
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Diabetes, Type 1 Diabetes
The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes
The purpose of this study is to determine if the drug Alpha-1 Antitrypsin (AAT, Aralast NP) will preserve beta-cell function and help slow the progression of type 1 diabetes.
- Trial name
- NCT01319331
- Testing
- Alpha 1-Antitrypsin (AAT, Aralast NP)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus, Type 1
Assessing Effectiveness of a Diabetes Navigator in Increasing Progression of Advanced Diabetes Technologies
The goal of this randomized control trial is to determine if the support of a Diabetes Navigator is more effective than standard care in improving uptake and use of advanced diabetes technology among patients with type 1 diabetes.
- Trial name
- IMPACT-T1D (NCT06229236)
- Testing
- Diabetes Navigator
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Johns Hopkins University
Type 1 Diabetes (T1D)
PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study
This Phase 3, multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety, and tolerability of SAB-142, a fully human anti-thymocyte globulin (h-ATG), in participants aged 5 to 40 years with…
- Trial name
- PRISE-hATG (NCT07670650)
- Testing
- SAB-142
- Where
- 4 sites in United States
- Volunteers
- 108 people
- Sponsor
- University of Florida
Type 1 Diabetes, Preservation of Insulin Secretion
Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes
Canakinumab is a fully human anti-interleukin-1β (anti-IL-1β) monoclonal antibody (IgG-1 class). Canakinumab is designed to bind to human IL-1β and to functionally neutralize the bioactivity of this pro-inflammatory cytokine.
- Conditions
- Type 1 Diabetes, Preservation of Insulin Secretion, Newly Diagnosed Type 1 Diabetes, Canakinumab in Type 1 Diabetes
- Trial name
- TN14 (NCT00947427)
- Testing
- canakinumab (anti IL-1beta)
- Where
- 12 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 2 Diabetes
Artificial Intelligence-based Methods to Predict Disease Progression in Youth With Type 2 Diabetes
Currently, clinicians are unable to predict a patient's risk of long-term disease progression and development of a long-term complication based on the data that is available to them.
- Trial name
- NCT07116902
- Testing
- phone application, Standard of Care (SOC)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Type 1 Diabetes Mellitus
A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (EU)
The purpose of this study is to determine whether Diamyd (rhGAD65 formulated in alum) is effective in preserving the body's own insulin producing capacity in patients recently diagnosed with type 1 diabetes.
- Trial name
- NCT00723411
- Testing
- rhGAD65
- Where
- 70 sites in Finland, France and 7 more
- Volunteers
- 334 people
- Sponsor
- Diamyd Therapeutics AB
Type 1 Diabetes (T1D)
Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo
The goal of this clinical trial is to learn if golimumab is effective at preventing progression to Stage 2 diabetes in participants with presymptomatic Type 1 Diabetes.
- Trial name
- NCT07683026
- Testing
- Golimumab
- Where
- United States
- Volunteers
- 255 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetic Retinopathy
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)
Diabetic retinopathy (DR) is a diabetes complication caused by damage to the small blood vessels inside the retina at the back of the eye. Diabetic retinopathy may cause mild vision problems or eventually blindness.
- Trial name
- ReFineDR (NCT04477707)
- Testing
- Finerenone (BAY94-8862)
- Where
- 62 sites in United States, Argentina and 13 more
- Volunteers
- 206 people
- Sponsor
- Bayer
Diabetic Nephropathy
Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy
diabetic nephropathy is one of the leading causes of end stage renal disease
- Trial name
- NCT03658317
- Testing
- renal arterial resistive index, uric acid level, serum urea and creatinine
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Assiut University
Blindness, Cataract
Long Term Follow-Up of Diabetic Retinopathy
The efficacy of laser photocoagulation treatment for diabetic retinopathy has been demonstrated by several National Eye Institute (NEI) sponsored clinical trials.
- Conditions
- Blindness, Cataract, Diabetes Mellitus, Diabetic Retinopathy
- Trial name
- NCT00001395
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Eye Institute (NEI)
Type 1 Diabetes, Autoimmunity
Prospective Assessment in Newborns for Diabetes Autoimmunity
This is an observational study designed to help researchers understand the genetics and pathogenesis of type 1 diabetes, and to identify biomarkers for disease and disease complication prediction.
- Trial name
- PANDA (NCT00649246)
- Where
- 3 sites in United States
- Volunteers
- 25,055 people, healthy volunteers welcome
- Sponsor
- Augusta University
Type 1 Diabetes
Description of Patients With Type 1 Diabetes Treated With Teplizumab
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the destruction of pancreatic β cells. T1D pathogenesis progresses through several stages: Stage 1 T1D includes the presence of β cell autoimmunity and thus…
- Trial name
- TEPLI-REAL (NCT06892002)
- Testing
- Teplizumab
- Where
- 27 sites in United States, Israel
- Volunteers
- 110 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1, Prediabetic State
Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies
The purpose of this study is to evaluate if immune-tolerance with Alum-formulated GAD (Diamyd), in combination with high dose Vitamin D3, may delay or stop the autoimmune process leading to clinical type 1 diabetes in…
- Trial name
- DiAPREV-IT2 (NCT02387164)
- Testing
- Alum-GAD, Vitamin D3
- Where
- Sweden
- Volunteers
- 26 people
- Sponsor
- Lund University
Type 1 Diabetes
Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes
This is a randomized, placebo-controlled phase II study to investigate if a prime and boost of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks apart, is safe and can preserve beta cell…
- Trial name
- NCT00435981
- Testing
- rhGAD65 formulated in Alhydrogel® (Diamyd®)
- Where
- 8 sites in Sweden
- Volunteers
- 70 people
- Sponsor
- Diamyd Therapeutics AB